- Home
- GLTO vs SONN Comparison
GLTO vs SONN Comparison
Compare GLTO & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- SONN
- Stock Information
- Founded
- GLTO 2011
- SONN N/A
- Country
- GLTO Denmark
- SONN United States
- Employees
- GLTO N/A
- SONN N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- GLTO Health Care
- SONN Health Care
- Exchange
- GLTO Nasdaq
- SONN Nasdaq
- Market Cap
- GLTO 4.4M
- SONN 3.8M
- IPO Year
- GLTO 2020
- SONN N/A
- Fundamental
- Price
- GLTO $3.35
- SONN $1.12
- Analyst Decision
- GLTO Buy
- SONN Strong Buy
- Analyst Count
- GLTO 1
- SONN 1
- Target Price
- GLTO $10.00
- SONN $20.00
- AVG Volume (30 Days)
- GLTO 18.8K
- SONN 45.9K
- Earning Date
- GLTO 08-11-2025
- SONN 08-13-2025
- Dividend Yield
- GLTO N/A
- SONN N/A
- EPS Growth
- GLTO N/A
- SONN N/A
- EPS
- GLTO N/A
- SONN N/A
- Revenue
- GLTO N/A
- SONN $1,000,000.00
- Revenue This Year
- GLTO N/A
- SONN $5,376.22
- Revenue Next Year
- GLTO N/A
- SONN N/A
- P/E Ratio
- GLTO N/A
- SONN N/A
- Revenue Growth
- GLTO N/A
- SONN 978.39
- 52 Week Low
- GLTO $2.01
- SONN $1.08
- 52 Week High
- GLTO $16.07
- SONN $10.02
- Technical
- Relative Strength Index (RSI)
- GLTO 65.19
- SONN 41.84
- Support Level
- GLTO $3.19
- SONN $1.10
- Resistance Level
- GLTO $3.63
- SONN $1.17
- Average True Range (ATR)
- GLTO 0.24
- SONN 0.06
- MACD
- GLTO 0.01
- SONN 0.00
- Stochastic Oscillator
- GLTO 79.37
- SONN 13.33
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.